Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

PURPOSE: In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from (131)I treatment. We investigated the incidence and duration of haematological toxicity and its risk factors in patients treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergsma, Hendrik, Konijnenberg, Mark W., Kam, Boen L. R., Teunissen, Jaap J. M., Kooij, Peter P., de Herder, Wouter W., Franssen, Gaston J. H., van Eijck, Casper H. J., Krenning, Eric P., Kwekkeboom, Dik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731438/
https://www.ncbi.nlm.nih.gov/pubmed/26419852
http://dx.doi.org/10.1007/s00259-015-3193-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731438/
https://www.ncbi.nlm.nih.gov/pubmed/26419852
http://dx.doi.org/10.1007/s00259-015-3193-4

Ejemplares similares